YAG Stock Chart & Stats
€2.08
€0.10(5.05%)
At close: 4:00 PM EDT
€2.08
€0.10(5.05%)
Day’s Range― - ―
52-Week Range€1.52 - €16.23
Previous CloseN/A
Volume0.00
Average Volume (3M)1.11K
Market Cap
€17.90M
Enterprise Value€13.53
Total Cash (Recent Filing)€31.72M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 17, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding9,974,998
10 Day Avg. Volume184
30 Day Avg. Volume1,115
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.87Price Target Upside567.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Debt On Balance SheetA debt-free capital structure reduces fixed financial obligations and interest risk, giving management flexibility to prioritize R&D and clinical programs. For a clinical-stage biotech, absence of leverage is a durable advantage that lowers bankruptcy risk and improves options for future financing or partnerships.
Completed Registered Direct Offering To Raise CashA recent registered direct offering providing immediate net proceeds materially extends near-term runway and funds clinical development. Structural benefit: it reduces immediate liquidity stress, buys time for clinical readouts or partnering discussions, and modestly lowers the urgency of dilutive emergency financings.
Focused Clinical-stage Breast Cancer PipelineA concentrated focus on breast cancer therapeutics creates domain expertise, clearer regulatory and clinical development pathways, and potential for targeted partnerships or licensing. This specialization supports durable competitive positioning within a defined therapeutic niche if clinical results prove positive.
Bears Say
Zero Revenue And Widening LossesPersistent zero revenue and growing operating losses mean the company cannot self-fund operations and remains fully dependent on external capital. Over months this reduces strategic optionality, increases dilution risk, and raises the bar for sustaining R&D programs without partner deals or successful clinical milestones.
Accelerating Negative Free Cash FlowSteadily increasing negative free cash flow is a structural weakness: it requires frequent external financings, constrains committed spend on trials, and can force unfavorable deal terms. Continued burn at current magnitudes materially elevates refinancing and execution risk over the coming 2-6 months.
Eroding Shareholders' Equity And Asset BaseSharp decline in equity and assets weakens the company’s capital cushion against trial setbacks or funding delays. A depleted balance sheet reduces negotiating leverage with partners or investors, increases reliance on dilutive raises, and heightens vulnerability to adverse events that could disrupt long-term development plans.
Atossa Therapeutics News
YAG FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was €1.52 and its highest was €16.23 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is €17.90M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 10 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -€0.96 earnings per share for the quarter, missing the consensus estimate of -€0.857 by -€0.104.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,974,998 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -€0.96 in its last earnings report, missing expectations of -€0.857. Following the earnings report the stock price went down -2.479%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in DE:YAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
YAG Stock 12 Month Forecast
Average Price Target
€13.87
▲(567.01% Upside)